BridgeBio Pharma, Inc. 8K

BridgeBio Pharma reported strong second quarter 2026 revenue growth led by Attruby, detailed progress and regulatory milestones across three late-stage programs, and highlighted a strengthened liquidity position following a subsequent $1 billion preferred equity financing to support multiple anticipated product launches.

On August 10, 2026, BridgeBio Pharma, Inc. reported its financial results for the quarter ended June 30, 2026, highlighting a sharp increase in total revenues to $243.7 million driven primarily by $222.4 million in U.S. Attruby net product revenue and higher royalties from BEYONTTRA, alongside continued net losses as the company ramps SG&A and R&D spending to support its late-stage pipeline. The company provided extensive pipeline and regulatory updates, noting that all three planned NDAs (BBP-418 for LGMD2I/R9, encaleret for ADH1, and oral infigratinib for achondroplasia) are now under FDA review, with BBP-418 and encaleret granted Priority Review and PDUFA dates of November 27, 2026 and May 8, 2027, respectively, and an NDA for infigratinib submitted with a targeted U.S. launch in mid-2027. BridgeBio also described new clinical and real-world evidence further differentiating Attruby (acoramidis) versus tafamidis, ongoing and planned clinical studies across multiple indications (including ASCEND-ATTR, RECLAIM-HP, CALIBRATE-PEDS, and PROPEL programs), and strategic commercial preparations for three potential launches. The company reported cash, cash equivalents, and marketable securities of $720.2 million as of June 30, 2026, excluding a $1 billion preferred equity financing that closed on July 1, 2026, which management stated will fund upcoming launches and continued pipeline expansion, and it announced plans to host a Commercial Day on October 8, 2026 in New York City to discuss launch strategy.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

8K

Source Type

fda

Accession

0001743881-26-000026

Alert Tier

7